Latest Breaking News On - Hepion pharmaceuticals investor relations - Page 6 : vimarsana.com

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a AMBITION

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a ‘AMBITION’ . Hepion Pharmaceuticals, Inc.May 6, 2021 GMT EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”), today announced that it has completed recruitment for its Phase 2a ‘AMBITION’ clinical trial, with all NASH patients in the 225 mg CRV431 dosing cohort now enrolled. “Over the past few months, the COVID-19 pandemic, compounded by the inclement weather experienced at some of our clinical trial sites in Texas, which resulted in power outages, presented difficulties in the recruitment of subjects for the second and final dosing cohort for our Phase 2a NASH trial,” said Dr. Robert Fos

United statesStephen kilmerToddm hobbsRobert fosterExchange commissionHepion pharmaceuticalsHepion pharmaceuticals investor relationsHepion pharmaceuticals incChief medicalArtificial intelligencePrivate securities litigation reform actHepion pharmaceuticalHepion pharmaceutical formஒன்றுபட்டது மாநிலங்களில்ஸ்டீபன் கில்மர்ராபர்ட் வளர்ப்பு

Hepion Pharmaceuticals, Inc : Hepion Pharmaceuticals to Present on CRV431 and AI-POW at NASH-TAG 2021

Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals to Present on CRV431 and AI-POW at NASH-TAG 2021 EDISON, NJ / ACCESSWIRE / March 11, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)( Hepion ), a clinical stage biopharmaceutical company focused on Artificial Intelligence ( AI )-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ( NASH ) and liver disease, today announced that it will present at the NASH-TAG 2021 Conference, being held virtually on March 11-13. The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in the diagnosis and therapy of NASH and liver fibrosis.

Stephen kilmerRobert fosterExchange commissionCompany phaseHepion pharmaceuticalsHepion pharmaceuticals investor relationsHepion pharmaceuticals incArtificial intelligenceNew pharmacologicalPrivate securities litigation reform actHepion pharmaceuticalHepion pharmaceutical formஸ்டீபன் கில்மர்ராபர்ட் வளர்ப்புபரிமாற்றம் தரகுநிறுவனம் கட்டம்

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

Stephen kilmerRobert fosterExchange commissionCompany phaseHepion pharmaceuticalsHepion pharmaceuticals investor relationsHepion pharmaceuticals incArtificial intelligenceNew pharmacologicalPrivate securities litigation reform actHepion pharmaceuticalHepion pharmaceutical formஸ்டீபன் கில்மர்ராபர்ட் வளர்ப்புபரிமாற்றம் தரகுநிறுவனம் கட்டம்

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.